Released Nov 14, 2022, before the open
10-Q filed Nov 14, 2022, 45 days after period end · 0001558370-22-017554
Q3 2022 · 10-Q
Revenue$14.18M$14.18M +17.7% vs Q3 2021+62.0% vs Q2 2022
Net Income-$3.57M-$3.57M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.07-$0.07 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$3,125,000N/M
Operating Cash Flowderived-$9,204,000N/M
Free Cash Flowderived-$9,262,000N/M
Margins · derived
Operating margin-22.0%−6.4 pt vs Q3 2021
Net margin-25.1%+9.7 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $14.18M | $12.05M | $10.79M | $14.25M |
| Net Income | -$3.57M | -$4.20M | -$4.44M | -$3.56M |
| EPS Diluted | -$0.07 | -$0.09 | -$0.14 | -$0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR